<DOC>
	<DOCNO>NCT01286753</DOCNO>
	<brief_summary>This open-label , multi-center study evaluate safety efficacy Vemurafenib ( RO5185426 ) participant metastatic unresectable papillary thyroid cancer ( PTC ) positive BRAF V600 mutation resistant radioactive iodine therapy . Participants receive vemurafenib 960 milligram ( mg ) orally twice daily progressive disease unacceptable toxicity occur .</brief_summary>
	<brief_title>A Study Vemurafenib ( RO5185426 ) Participants With Metastatic Unresectable Papillary Thyroid Cancer Positive BRAF V600 Mutation</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<criteria>Adult participant . &gt; /= 18 year age Histologically confirm metastatic unresectable papillary thyroid cancer standard curative palliative measure exist longer effective ; participant whose tumor exhibit area `` histology '' may enrol , provide tumor histology remain predominantly papillary Positive BRAF V600 mutation ( Roche Cobas 4800 BRAF V600 Mutation Test ) Radioactive Iodine resistant disease Prior therapy exclude ( Cohort 1 , TKI Naive ) include ( Cohort 2 , TKI Experienced ) TKI Clinically relevant disease progression accord RECIST criterion within prior 14 month Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate hematological , renal liver function Histological diagnosis papillary PTC , include squamous cell variant PTC PTC area squamous metaplasia Active untreated central nervous system metastases History know carcinomatous meningitis Anticipated ongoing administration anticancer therapy administer study Active squamous cell skin cancer excise adequately heal post excision Previous treatment agent specifically selectively target MEK BRAF pathway Prior radiotherapy measurable lesion Clinically relevant cardiovascular disease event within prior 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>